Home > Haematology > ASH 2020 > Multiple Myeloma > Better survival with upfront autoSCT versus bortezomib-based intensification

Better survival with upfront autoSCT versus bortezomib-based intensification

Presented By
Prof. Michele Cavo, University of Bologna, Italy
Conference
ASH 2020
Trial
Phase 3, EMN02/HO95
At an extended median follow-up of 75 months, high-dose intensification therapy with autologous haematopoietic stem-cell transplantation (autoSCT) resulted in significantly longer overall survival (OS) in comparison with bortezomib-melphalan-prednisone (VMP). The OS benefit with autoSCT was preserved across subgroups of patients. In the phase 3 EMN02/HO95 study (NCT01208766), newly diagnosed multiple myeloma (MM) patients were randomised to intensification therapy with either upfront autoSCT or VMP. Results of the final analysis demonstrated that progression-free survival (PFS) was significantly improved with autoSCT compared with VMP (median 57 vs 42 months; HR 0.73; adjusted P=0.0001). However, no difference between these groups was found in terms of secondary endpoint OS (HR 0.90; adjusted P=0.35) [1]. Thereafter, patients were re-randomised to consolidation th...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on